RSV disease in infants and young children: Can we see a brighter future?
Human Vaccines & Immunotherapeutics, 2022 Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations
Eugenio Baraldi +7 more
doaj +2 more sources
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children [PDF]
The Journal of Infectious Diseases, 2022 Abstract Background This United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion. Methods
Cunningham, Coleen K +23 more
openaire +4 more sources
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
Cochrane Database of Systematic Reviews, 2021 BACKGROUND Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
Luis Garegnani +5 more
openalex +3 more sources
Human Vaccines & Immunotherapeutics, 2021 Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults.
Antonios O. Aliprantis +17 more
doaj +2 more sources
The incidence and clinical burden of respiratory syncytial virus disease identified through hospital outpatient presentations in Kenyan children [PDF]
, 2012 There is little information that describe the burden of respiratory syncytial virus (RSV) associated disease in the tropical African outpatient setting. Methods We studied a systematic sample of children aged
Ann Bett +35 more
core +23 more sources
Global molecular diversity of RSV – the “INFORM RSV” study [PDF]
BMC Infectious Diseases, 2020 Abstract Background Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV.
Langedijk, Annefleur C. +28 more
+10 more sources
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
New England Journal of Medicine, 2023 BACKGROUND Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
B. Kampmann +40 more
semanticscholar +1 more source
P-1423. Effectiveness of nirsevimab against RSV-related hospitalizations in a pediatric primary care network using target trial emulation [PDF]
Open Forum Infect DisMahaa M Ahmed +4 more
europepmc +2 more sources
Estudios de Lingüística del Español, 2021 El humor es un fenómeno interdisciplinar a la vez que polifuncional. Como género, ha dado lugar a distintos formatos (chiste, monólogo, parodia, sketch…), pero es, además, un poderoso recurso del que se sirven otros géneros no propiamente humorísticos ...
Mar Galindo Merino +1 more
doaj +1 more source
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
New England Journal of Medicine, 2022 BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.
L. Hammitt +17 more
semanticscholar +1 more source